239 related articles for article (PubMed ID: 27693373)
41. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
[TBL] [Abstract][Full Text] [Related]
42. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
43. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
44. Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp.
Calixto SL; Glanzmann N; Xavier Silveira MM; da Trindade Granato J; Gorza Scopel KK; Torres de Aguiar T; DaMatta RA; Macedo GC; da Silva AD; Coimbra ES
Chem Biol Interact; 2018 Sep; 293():141-151. PubMed ID: 30098941
[TBL] [Abstract][Full Text] [Related]
45. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
46. Amiodarone and itraconazole improve the activity of pentavalent antimonial in the treatment of experimental cutaneous leishmaniasis.
Anversa L; Salles Tiburcio MG; Batista LR; Cuba MB; Nogueira Nascentes GA; Martins TY; Richini Pereira VB; Ruiz LDS; Dias da Silva VJ; Ramirez LE
Int J Antimicrob Agents; 2017 Aug; 50(2):159-165. PubMed ID: 28668672
[TBL] [Abstract][Full Text] [Related]
47. Photodynamic therapy using ultradeformable liposomes loaded with chlorine aluminum phthalocyanine against L. (V.) braziliensis experimental models.
Escobar P; Vera AM; Neira LF; Velásquez AO; Carreño H
Exp Parasitol; 2018 Nov; 194():45-52. PubMed ID: 30257189
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
[TBL] [Abstract][Full Text] [Related]
50. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
51. Leishmanicidal activity of primary S-nitrosothiols against Leishmania major and Leishmania amazonensis: implications for the treatment of cutaneous leishmaniasis.
de Souza GF; Yokoyama-Yasunaka JK; Seabra AB; Miguel DC; de Oliveira MG; Uliana SR
Nitric Oxide; 2006 Nov; 15(3):209-16. PubMed ID: 16527502
[TBL] [Abstract][Full Text] [Related]
52. Experimental therapeutic assays of Tephrosia vogelii against Leishmania major infection in murine model: in vitro and in vivo.
Marango SN; Khayeka-Wandabwa C; Makwali JA; Jumba BN; Choge JK; Adino EO; Anjili CO
BMC Res Notes; 2017 Dec; 10(1):698. PubMed ID: 29208030
[TBL] [Abstract][Full Text] [Related]
53. Grandiflorenic acid promotes death of promastigotes via apoptosis-like mechanism and affects amastigotes by increasing total iron bound capacity.
Bortoleti BTDS; Gonçalves MD; Tomiotto-Pellissier F; Miranda-Sapla MM; Assolini JP; Carloto ACM; de Carvalho PGC; Cardoso ILA; Simão ANC; Arakawa NS; Costa IN; Conchon-Costa I; Pavanelli WR
Phytomedicine; 2018 Jul; 46():11-20. PubMed ID: 30097110
[TBL] [Abstract][Full Text] [Related]
54. Intermediate/borderline disseminated cutaneous leishmaniasis.
Paniz Mondolfi AE; Duffey GB; Horton LE; Tirado M; Reyes Jaimes O; Perez-Alvarez A; Zerpa O
Int J Dermatol; 2013 Apr; 52(4):446-55. PubMed ID: 23231577
[TBL] [Abstract][Full Text] [Related]
55. In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species.
Inocêncio da Luz RA; Vermeersch M; Deschacht M; Hendrickx S; Van Assche T; Cos P; Maes L
J Antimicrob Chemother; 2011 Feb; 66(2):350-3. PubMed ID: 21131319
[TBL] [Abstract][Full Text] [Related]
56. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
57. Comparative study of viscerotropic pathogenicity of Leishmania major amastigotes and promastigotes based on identification of mitochondrial and nucleus sequences.
Spotin A; Parvizi P
Parasitol Res; 2016 Mar; 115(3):1221-8. PubMed ID: 26631188
[TBL] [Abstract][Full Text] [Related]
58. The efficacy of 2-nitrovinylfuran derivatives against Leishmania in vitro and in vivo.
Sifontes-Rodríguez S; Monzote-Fidalgo L; Castañedo-Cancio N; Montalvo-Álvarez AM; López-Hernández Y; Diogo NM; Infante-Bourzac JF; Pérez-Martín O; Meneses-Marcel A; García-Trevijano JA; Cabrera-Pérez MÁ
Mem Inst Oswaldo Cruz; 2015 Apr; 110(2):166-73. PubMed ID: 25946239
[TBL] [Abstract][Full Text] [Related]
59. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
[TBL] [Abstract][Full Text] [Related]
60. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice.
Nelson KG; Bishop JV; Ryan RO; Titus R
Antimicrob Agents Chemother; 2006 Apr; 50(4):1238-44. PubMed ID: 16569834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
